Form 4: X4 Pharmaceuticals CFO Sells Shares

X4 Pharmaceuticals CFO David Kirske reported a sale of 16,961 common shares on May 12, 2026, for tax obligations.

Summary

• David Kirske, Chief Financial Officer of X4 Pharmaceuticals, Inc. (XFOR), sold 16,961 shares of common stock on May 12, 2026.
• The sale was conducted to cover personal income tax obligations related to the settlement of restricted stock units.
• The shares were sold at a weighted average price of $4.2934, with individual transactions ranging from $4.20 to $4.45.
• Following the transaction, Mr. Kirske beneficially owns 176,293 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale is attributed to a standard tax obligation rather than a lack of confidence in the company's prospects.

Negatives

• A significant number of shares were sold by a key executive, which could be perceived negatively by the market, although the reason is stated as tax coverage.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, while often routine for tax-related stock sales by executives, can sometimes be interpreted by the market as a signal of an executive's confidence in the company's future. The specific reason for this sale (tax coverage) mitigates some of that concern, but the volume of shares sold warrants attention.

Stakeholder Impact

• Shareholders may note the sale of shares by the CFO, although the stated reason for the transaction is to cover tax obligations, which is a common and expected event for executives receiving equity compensation.

Key Dates

Keywords

X4 Pharmaceuticals, XFOR, Form 4, insider trading, stock sale, CFO, David Kirske, restricted stock units, tax obligation